trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['bcsm']
 agree- and letting our pathology colleagues know that the difference between her-2 0 and 1+ is now actionable. super important! #bcsm #asco22 #tdxd #her2low
Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine.